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Background: The pathological appearance of idiopathic pleuroparenchymal fibroelastosis (IPPFE) with hematoxylin-eosin
staining is similar to that of usual interstitial pneumonia (UIP) in patients with idiopathic pulmonary fibrosis (IPF). The
amount of elastic fibers (EF) and detailed differences between IPPFE and IPF have not been fully elucidated. The aim of
this study was to quantify the EF and identify the differences between IPPFE and IPF.
Methods: We evaluated six patients with IPPFE and 28 patients with IPF who underwent surgical lung biopsy or
autopsy. The patients’ clinical history, physical findings, chest high-resolution computed tomography (HRCT) findings,
and pathological features of lung specimens were retrospectively evaluated. The amounts of EF in lung specimens
were quantified with Weigert’s staining using a camera with a charge-coupled device and analytic software in both
groups.
Results: Fewer patients with IPPFE than IPF had fine crackles (50.0% vs. 96.4%, p = 0.012). Patients with IPPFE had a
lower forced vital capacity (62.7 ± 10.9% vs. 88.6 ± 21.9% predicted, p = 0.009), higher consolidation scores on HRCT
(1.7 ± 0.8 vs. 0.3 ± 0.5, p < 0.0001), lower body mass indices (17.9 ± 0.9 vs. 24.3 ± 2.8, p < 0.0001), and more
pneumothoraces than did patients with IPF (66.7 vs. 3.6%, p = 0.002). Lung specimens from patients with IPPFE had
more than twice the amount of EF than did those from patients with IPF (28.5 ± 3.3% vs. 12.1 ± 4.4%, p < 0.0001). The
amount of EF in the lower lobes was significantly lower than that in the upper lobes, even in the same patient with
IPPFE (23.6 ± 2.4% vs. 32.4 ± 5.5%, p = 0.048). However, the amount of EF in the lower lobes of patients with IPPFE was
still higher than that of patients with IPF (23.6 ± 2.4% vs. 12.2 ± 4.4%, p < 0.0001).
Conclusion: More than twice the amount of EF was found in patients with IPPFE than in those with IPF. Even in the
lower lobes, the amount of EF was higher in patients with IPPFE than in those with IPF, although the distribution of
lung EF was heterogeneous in IPPFE specimens.
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Figure 1 Representative findings of high-resolution computed
tomography (HRCT) and surgical lung biopsy specimens of a
patient with idiopathic pleuroparenchymal fibroelastosis
(IPPFE). HRCT shows pleural thickening and subpleural
consolidation opacities in the upper lobes (A). A lung section
stained with hematoxylin and eosin shows subpleural fibrosis with
an abrupt transition to normal lung parenchyma and fibroblastic
foci, similar to that seen in usual interstitial pneumonia (B, ×12.5).
Pleural fibrosis was also seen. A lung specimen with Elastica van
Gieson staining demonstrates deposition of dense elastic fibers
(elastosis) in a subpleural fibrotic lung lesion (C, ×12.5).
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Idiopathic pleuroparenchymal fibroelastosis (IPPFE) is a
rare disease that was recently classified as a rare idiopathic
interstitial pneumonias (IIPs) together with idiopathic
lymphoid interstitial pneumonia in an official American
Thoracic Society (ATS)/European Respiratory Society
(ERS) statement on the international multidisciplinary
classification of the IIPs [1]. IPPFE was first described by
Frankel et al. in 2004 [2], which showed upper lobe-
predominant volume loss, pleural thickening, and pro-
minent subpleural fibroelastosis [2]. IPPFE has clinical,
radiological, and pathological features similar to those of
idiopathic pulmonary upper lobe fibrosis (IPUF), which
was first reported in a Japanese paper by Amitani et al. in
1992 [3]. These two disorders are considered to be within
the same spectrum [4].
The pathological features of IPPFE, which include dense
subpleural fibroelastosis on elastic staining, are quite spe-
cific for this disorder. However, these pathological features
on hematoxylin-eosin (HE) staining, including perilobular
collagen deposition with abrupt transition to underlying
normal parenchyma and fibroblastic foci, are similar to
those of usual interstitial pneumonia (UIP) in patients
with idiopathic pulmonary fibrosis (IPF) [5]. The UIP-
pattern has also been found in the lower lobes of patients
with IPPFE [6], and patients with IPPFE are sometimes
misdiagnosed with IPF because of their similar patho-
logical findings on HE staining [7]. However, the precise
differences between IPPFE/IPUF and IPF have not yet
been studied.
All organs contain fibrous connective tissue, which
comprises collagen, reticular, and elastic fibers (EF). The
proportion of collagen and elastic fibers determines an
organ’s physical flexibility and elasticity. In patients with
lung fibrosis, the increased proportion of EF within fi-
brotic tissue reduces compliance and makes the lungs
stiff. We recently reported that an increased amount of
EF in surgical lung biopsy specimens is an independent
predictor of a poor prognosis in patients with IPF [8].
Accumulation of dense EF in the subpleural parenchyma
is another specific pathological feature of IPPFE [2].
However, the details regarding the amount and distribu-
tion of EF in patients with IPPFE remain unknown, and
the difference in the amount of EF between IPPFE and
IPF has not been quantitatively evaluated.
In the present study, we compared the clinical, radio-
logical, and pathological findings of IPPFE with those of
IPF. In addition, we quantified the amount of EF in lung
specimens from patients with IPPFE or IPF using a cam-
era with charge-coupled device (CCD) and analytic soft-
ware. IPPFE lung specimens had more than twice the
amount of EF found in IPF lung specimens. Fur-
thermore, whereas the distribution of lung EF was quite
heterogeneous in IPPFE specimens, the amount of EF inthe lower lobes was still higher in patients with IPPFE
than in those with IPF.
Methods
Study population
Six consecutive patients with IPPFE who underwent sur-
gical lung biopsy or autopsy in our hospital or affiliated
hospitals from 2010 to 2011 were evaluated. The patho-
logical diagnosis of IPPFE was based on a previous report
by Frankel et al. [2]. Briefly, the diagnosis of IPPFE was
based on the presence of prominent subpleural fibro-
elastosis, sparing of the parenchyma distant from the
pleura, and a relatively abrupt border between the fibroe-
lastosis and the underlying normal parenchyma (Figure 1B
and C). Clinical, radiological, and pathological data of
these patients were retrospectively reviewed. Patients who
met the criteria for any connective tissue disorders were
excluded from this study.
Twenty-eight consecutive patients with IPF who under-
went surgical lung biopsy in our hospital from 1997 to
2007 were also evaluated in this study. The initial diagno-
sis of IPF was based on the latest diagnostic criteria of that
period. All 28 patients also met the 2011 IPF consensus
criteria of the ATS, ERS, Japanese Respiratory Society
(JRS), and Latin American Thoracic Association (ALAT)
[5]. The histologic features of UIP were based on a pre-
viously published reports [5,9]. No lung specimens had a
“not UIP pattern” as defined by the IPF consensus criteria
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monia, granulomas, marked interstitial inflammatory
cell infiltrate away from honeycombing, or predominant
airway-centered changes) [5]. The study protocol was
approved by the Ethics Committee of Hamamatsu Uni-
versity School of Medicine (approval number 24-167).
Quantification of EF
All available lung specimens were examined. Samples
were fixed in neutral buffered 10% formalin and embed-
ded in paraffin. Staining was performed on 4-μm sections
mounted on glass slides. Sections were stained by HE or
Weigert’s resorcin-fuchsin solution. Images of sections
stained with Weigert’s elastic staining were collected using
a microscope with a CCD camera (DP21; Olympus,
Tokyo, Japan). Images of fibrotic lesions at × 40 magnifica-
tion were obtained from all slides (Figure 2A). For each
image, the area occupied by EF was quantified using im-
aging software (Image J; National Institutes of Health,
Bethesda, MD and Photoshop Elements; Adobe, San Jose,
CA), according to our previous report [8]. Images were
converted to gray scale, then binarized with two different
thresholds to quantify the area of the whole fibrotic lung
lesion (Figure 2B, blue area) and the area of EF (Figure 2C,
red area). The proportion of EF in the fibrotic interstitial
area was calculated by dividing the number of pixels con-
taining EF (red area) by that of the whole fibrotic lesion
(blue area). For each patient, the mean proportion of EFC
A
Figure 2 Images of lung sections in a patient with idiopathic pleurop
microscope with a camera equipped with a charge-coupled device and imag
van Gieson (A), and imaged lesions at 40x magnification in all specimens wer
the area containing the fibrotic lung lesion using software (B, blue area). The
(C, red area). The concentration of elastic fibers (EF score) in the fibrotic area w
that of the target fibrotic lung lesion (blue area). Surgical biopsy images fromin all histological images was calculated and expressed as
a percentage (the EF score).
Evaluation of other pathological findings
The investigators examining the histological specimens
also evaluated the collagen deposition, cellularity, and
organization in the air spaces. The severity of each of
these findings was scored on a scale from 0 to 3 (0,
none; 1, mild; 2, moderate; 3, severe). The presence of
honeycombing, lymphoid hyperplasia, and pleuritis was
also recorded. These findings were reviewed by two ob-
servers and the agreement rates between the observers
were evaluated by weighted-kappa coefficients. The co-
efficients ranged from 0.34 to 0.68. When the score dif-
fered between the observers, a consensus was reached
after discussion.
Evaluation of high-resolution computed tomography
findings
The extent of lung fibrosis was measured using high-
resolution computed tomography (HRCT) on slices taken
at the tracheal bifurcation, the base of the lower lobes, and
at the midpoint. The extent of fibrosis in each lobe was
scored using the following system: 0, none; 1, 1–10%; 2,
11–25%; 3, 26–50%; 4, 51–75%; and 5, 76–100%. The sum
of the scores from five lobes (0–25) was used to express
the extent of fibrosis throughout each patient’s lungs. The
severity of ground-glass opacity and consolidation wasB
arenchymal fibroelastosis (IPPFE). The images were made using a
e analysis software. Surgical lung specimens were stained with Elastica
e captured. Images were changed to gray scale, then binarized to detect
images were binarized with another threshold to estimate elastic fibers
as calculated by dividing the pixel number of elastic fibers (red area) by
one patient with an EF score of 27.5% are shown.
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evaluation. Finally, the presence of honeycombing on
HRCT was also evaluated. These findings were reviewed
by two observers; the agreement rates between them were
evaluated by weighted-kappa coefficients. The coefficients
ranged from 0.34 to 0.83. When the score differed be-
tween the observers, a consensus was reached after
discussion.
Data collection
Clinical data, including sex, age, smoking history, symp-
toms, treatment, and survival were obtained from the
patients’ medical records. Laboratory findings, pulmo-
nary function tests results, and bronchoalveolar lavage
(BAL) data at the time of surgical lung biopsy or before
autopsy were also recorded.
Statistical analysis
Statistical analyses were performed using StatView J-4.5
(SAS Institute, Inc., Cary, NC, US). Categorical data
were compared using the chi-square test or Fisher’s
exact probability test for independence. Continuous data
were compared using a paired or unpaired Student’s
t-test. Discontinuous data were compared using Mann-
Whitney’s U-test. The relationship between the EF score
and serial data was analyzed using Pearson’s correlation
coefficient, and that between the EF score and discrete
variable data was analyzed using Spearman’s rank cor-
relation coefficient. The overall survival of each group
was estimated by Kaplan-Meier curves. The log-rank test
was used to compare survival between the two groups.
All tests were two-sided, and statistical significance was
defined as p < 0.05.
Results
Clinical characteristics of patients with IPPFE
Six consecutive patients with IPPFE who underwent
surgical lung biopsy or autopsy were evaluated. One pa-
tient was autopsied after acute exacerbation of lung
disease. Antinuclear antibody was positive at 1:40 in
three patients, and rheumatoid factor was positive in
two patients. Anti-cyclic citrullinated peptide antibody
was positive in one patient. Anti-double-strand DNA
antibody and anti-cardiolipin β2 glycoprotein 1 antibody
were positive in one patient. However, no patients met
the criteria for any connective tissue disorders. No
patients had a family history of interstitial lung disease
or a history of dust exposure. One patient had under-
gone chemotherapy for gingival carcinoma. Although re-
peated bacterial pneumonia had occurred in one patient,
no patients had a history of fungal infection such as pul-
monary aspergillosis. Refractory pneumothorax appeared
shortly after the surgical lung biopsy in one patient.Representative HRCT and surgical lung biopsy findings
specimens from one patient with IPPFE are shown in
Figure 1. HRCT showed pleural thickening and subpleural
consolidation opacities in the upper lobes (Figure 1A). An
HE-stained lung section revealed subpleural fibrosis with
abrupt transition to underlying normal lung parenchyma
and fibroblastic foci, similar to UIP (Figure 1B). Pleural
fibrosis was also seen. Deposition of dense EF (elastosis)
in subpleural fibrotic lung lesions, which is a specific
histological finding of IPPFE, was seen on a section with
Elastica-van Gieson (EVG) staining (Figure 1C).
Comparison between IPPFE and IPF: clinical
characteristics
The clinical characteristics of patients with IPPFE and IPF
are compared in Table 1. Five of the six patients with
IPPFE were male, and their mean age of the six patients
was 69.2 years. The observation period was 39.8 ± 29.2
(mean ± SD) months. Patients with IPPFE had a higher
proportion of never-smokers (50% vs. 7.1%, p = 0.011)
and a lower mean body mass index (17.9 vs. 24.3 (mean),
p < 0.0001) than did patients with IPF. Fewer patients with
IPPFE than IPF had fine crackles at the time of diagnosis
(50.0% vs. 96.4%, p = 0.012). In addition, patients with
IPPFE had more pneumothoraces during the observation
period (66.7% vs. 3.6%, p = 0.002). Refractory pneumo-
thorax appeared shortly after surgical lung biopsy in one
patient with IPPFE. Although the proportion of patients
who underwent medical check-ups to detect interstitial
pneumonia was not different between the two groups, the
period from detection of interstitial pneumonia to acquisi-
tion of lung specimens was significantly longer in patients
with IPPFE than in those with IPF (73.3 vs. 29.7 months,
p = 0.012). Four of the six patients with IPPFE received
therapeutic interventions. Steroid treatment was started in
one patient, whilst pirfenidone was administrated to the
other three patients. However, these treatments showed
no therapeutic effects, and three of the six patients with
IPPFE died during the study period. One died of acute
exacerbation of IPPFE, and the other two died of chronic
disease progression.
Comparison between IPPFE and IPF: laboratory,
physiologic, and BAL data
The laboratory, physiologic, and BAL data between the
patients with IPPFE and IPF are compared in Table 2. The
serum levels of interstitial pneumonia markers, such as
lactate dehydrogenase (LDH), Krebs von den Lungen-6
(KL-6), and surfactant protein D (SP-D), were not different
between the two groups. The forced vital capacity (FVC)
was significantly lower in patients with IPPFE than in those
with IPF (62.7% vs. 88.6% predicted, p = 0.009), although
the diffusion lung capacity for carbon monoxide (DLCO)
was not significantly different (p = 0.395). Furthermore, the
Table 2 Comparison between idiopathic
pleuroparenchymal fibroelastosis (IPPFE) and idiopathic
pulmonary fibrosis (IPF): laboratory, physiologic, and
bronchoalveolar lavage data
IPPFE (n = 6) IPF (n = 28) p value
Laboratory findings
Serum LDH, U/L 192 ± 37 223 ± 43 0.106
Serum KL-6, U/ml 755 ± 473 1282 ± 888 0.199
Serum SP-D, ng/ml 298 ± 346 222 ± 136 0.527
SP-D/KL-6 0.38 ± 0.20 0.26 ± 0.18 0.168
Physiologic
Resting PaO2, mm Hg 77.6 ± 11.5 83.2 ± 11.0 0.363
Resting PaCO2, mm Hg 43.5 ± 7.2 40.6 ± 3.1 0.138
FVC, L 1.97 ± 0.42 2.91 ± 0.91 0.021
FVC, % predicted 62.7 ± 10.9 88.6 ± 21.9 0.009
DLCO, % predicted 77.9 ± 13.4 89.0 ± 26.1 0.395
ΔFVC in 12 mo, L -0.51 ± 0.35 -0.32 ± 0.38 0.364
BAL fluid cell analysis
Lymphocytes, % 6.0 ± 4.5 5.2 ± 7.0 0.782
Neutrophils, % 2.5 ± 3.3 0.6 ± 0.8 0.018
Eosinophils, % 1.7 ± 2.0 0.4 ± 0.6 0.011
Data are presented as mean ± SD.
Data are analysed with Student’s t-test.
Definition of abbreviations: FVC forced vital capacity, FEV1 forced expiratory
volume in 1 second, DLCO diffusion lung capacity for carbon monoxide,
BAL bronchoalveolar lavage.
Table 1 Comparison between idiopathic pleuroparenchymal fibroelastosis (IPPFE) and idiopathic pulmonary fibrosis
(IPF): clinical characteristics
IPPFE (n = 6) IPF (n = 28) p value
Sex, male/female 5/1 26/2 0.452*
Age at biopsy, yr 69.2 ± 3.9 61.4 ± 9.9 0.072
Smoking history, current/ex/never 0/3/3 13/13/2 0.011*
Pack-year of smoking 29.3 ± 33.1 66.8 ± 97.4 0.363
Detection by medical check-up, n (%) 3 (50) 21 (75.0) 0.328*
Respiratory symptoms at biopsy, n (%) 6 (100) 19 (67.9) 0.162*
Body mass index, kg/m2 17.9 ± 0.9 24.3 ± 2.8 <0.0001
Clubbing of finger, n (%) 1 (16.7) 6 (21.4) 0.999*
Fine crackles, n (%) 3 (50) 27 (96.4) 0.012*
Pneumothorax, n (%) 4 (66.7) 1 (3.6) 0.002*
Acute exacerbation, n (%) 1 (16.7) 6 (21.4) 0.999*
Therapeutic intervention, n (%) 4 (66.7) 15 (53.6) 0.672*
Period from detection of IP until acquisition of lung specimens 73.3 ± 46.1 29.7 ± 34.3 0.012
Observation period, mo 39.8 ± 29.2 67.8 ± 46.7 0.206
Death, n (%) 3 (50.0) 12 (42.9) 0.999*
Data are presented as n, mean ± SD or n (%).
Data were analyzed with Student’s t-test or *Fisher’s exact probability test.
Abbreviations: IPPFE idiopathic pleuroparenchymal fibroelastosis, IPF idiopathic pulmonary fibrosis, IP interstitial pneumonia.
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were higher in patients with IPPFE than in those with IPF
(2.5% vs. 0.6%, p = 0.018 and 1.7% vs. 0.4%, p = 0.011,
respectively).
Comparison between IPPFE and IPF: HRCT and lung
specimen findings
The HRCT and lung specimen findings in patients with
IPPFE or IPF are summarized in Table 3. All patients with
IPPFE showed upper lobe predominance and pleural
thickening on HRCT (p < 0.0001). Higher consolidation
scores on HRCT were found in patients with IPPFE than
in those with IPF (1.7 vs. 0.3, p = 0.004). No significant
differences were found in the other HRCT findings, such
as the extent score or ground glass score.
HE-stained lung specimens showed pleural fibrosis or
pleuritis underneath the dense subpleural fibroelastosis
in five of the six patients with IPPFE (p < 0.0001). Sig-
nificantly higher organizing pneumonia scores in the
alveolar space were found in patients with IPPFE than
in those with IPF (1.8 vs. 0.6, p = 0.003). Although the
abrupt transition between the subpleural fibroelastosis
and underlying normal lung area was more prominent
in patients with IPPFE, no significant differences were
found in the other pathological findings, such as the col-
lagen deposition score or cellularity score.
Quantitative analysis of EF in fibrotic lung lesions
Using a CCD-camera and analytic software, abundant EF
were found in the fibrotic lung lesions with EVG staining,
Table 3 Comparison between idiopathic pleuroparenchymal fibroelastosis (IPPFE) and idiopathic pulmonary fibrosis
(IPF): findings on high resolution computed tomography (HRCT) and lung specimens
IPPFE (n = 6) IPF (n = 28) p value
Findings on HRCT
Extent score, 0-25 9.8 ± 2.6 8.8 ± 3.7 0.366
Upper lobe predominant distribution, n (%) 6 (100) 0 (0) <0.0001*
Reticulation score, 0-3 1.3 ± 0.5 1.8 ± 0.7 0.161
Glass score, 0-3 1.5 ± 0.8 1.7 ± 0.7 0.429
Consolidation score, 0-3 1.7 ± 0.8 0.3 ± 0.5 0.004
Existence of honeycombing, n (%) 0 (0) 10 (35.7) 0.148*
Emphysema score, 0-3 0 0.7 ± 0.9 0.078
Pleural thickening, n (%) 6 (100) 2 (7.1) <0.0001*
Findings on surgical lung biopsy specimens
Collagen deposition score, 0-3 2.0 ± 0 2.4 ± 0.8 0.175
Existence of microscopic honeycombing, n (%) 1 (16.7) 17 (60.7) 0.078*
Organizing pneumonia score, 0-3 1.8 ± 0.4 0.6 ± 0.7 0.003
Cellularity score in interstitium, 0-3 1.5 ± 0.5 1.3 ± 0.6 0.456
Lymphoid hyperplasia, n (%) 0 (0) 0 (0) NA.
Pleural fibrosis, pleuritis, n (%) 5 (83.3) 0 (0) <0.0001*
Data are presented as mean ± SD or, n (%).
Data are analysed with Mann-Whitney’s U-test or *Fisher’s exact probability test.
HRCT high resolution computed tomography, NA not applicable.
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tative analytic method (Figure 2). The proportion of EF in
fibrotic areas (the EF score) was assessed according to the
procedure described in the Methods section. All EF scores
are shown in Figure 3. EF scores in patients with IPPFE
were significantly higher than those in patients with IPF
(median, 28.3% [range, 25.1-35.6%] vs. 11.0% [range, 5.1-
23.3%], p < 0.0001). In patients with IPPFE, no correlations
were found between EF scores and %FVC (r = -0.058,
p = 0.919) (Additional file 1: Figure S1A), between EF
scores and %DLCO (r = -0.548, p = 0.384) (Additional
file 1: Figure S1B), between EF scores and the change
in FVC 12 months after biopsy (r = 0.446, p = 0.631)
(Additional file 1: Figure S1C), or between EF scores
and the period from detection of interstitial pneumonia
until acquisition of lung specimens (r = 0.424, p = 0.433)
(Additional file 1: Figure S1D).
Heterogeneity in the deposition of lung EF in IPPFE
Lung specimens were obtained from two different lobes in
five of the six patients with IPPFE. EVG-stained sections
showed fewer EF in the right lower lobe (Figure 4D-F)
than that in the right upper lobe (Figure 4A-C) in the
same patient with IPPFE. In this patient, the EF score in
the lower lobe was 20.3% (Figure 4F), whilst that in the
upper lobe was 32.4% (Figure 4C). All EF scores in both
lobes are shown in Figure 5A. The EF scores in the lower
lobes were significantly lower than those in the upper
lobes in patients with IPPFE (median, 24.2% [range, 20.3-26.5%] vs. 32.4% [range, 24.9-39.6%], p = 0.048). Con-
versely, in patients with IPF, the difference in EF scores
between the lower lobes and upper lobes was not sig-
nificant (14.6 vs. 17.2%, p = 0.154) (Figure 5B and C).
However, even in the lower lobes, EF scores in patients
with IPPFE were still higher than those in patients with
IPF (p < 0.0001) (Figure 5C) as well as those in the upper
lobes (p = 0.0007) (Figure 5B).
Discussion
IPPFE was recently classified as a rare IIP in an official
ATS/ERS statement [1] and has attracted a great deal of
attention. Pathologically, IPPFE shows perilobular col-
lagen deposition with an abrupt transition to underlying
normal parenchyma [10]. This finding on HE staining,
without elastic staining, is similar to that of IPF/UIP,
which is the most common type of IIP and has a grave
prognosis [5]. Although some patients with IPPFE have
reportedly lived for 7 years or more [2,6], many die be-
fore this period [6,11].
As described above, IPPFE has pathological and clinical
features similar to those of IPF; however, the precise dif-
ferences between IPPFE and IPF have not yet been fully
elucidated. In this study, a lower incidence of the fine
crackles at the time of diagnosis, more pneumothoraces, a
higher proportion of never-smokers, and lower body mass
indices were seen among patients with IPPFE than with
IPF. The lower body mass indices may also have




















Figure 3 Total elastic fiber scores of all patients with idiopathic
pleuroparenchymal fibroelastosis (IPPFE) or idiopathic
pulmonary fibrosis (IPF). The proportion of elastic fibers (EF score)
was calculated by dividing the pixel number of elastic fibers by that of
the target fibrotic lung lesion. The horizontal bar represents the
median. The median value in patients with IPPFE was 28.3% (range,
25.1-35.6%), and that in patients with IPF was 11.0% (range, 5.1-23.3%).
Higher amounts of elastic fiber were seen in the 6 patients with IPPFE






Figure 4 Comparison of fibroelastosis between the upper and
lower lobes in a patient with idiopathic pleuroparenchymal
fibroelastosis (IPPFE). High-resolution computed tomography
(HRCT) of the right upper lobe shows pleural thickening and subpleural
consolidation opacities (A). A lung section stained with hematoxylin
and eosin (HE) shows subpleural fibrosis with an abrupt transition to
normal lung parenchyma, similar to usual interstitial pneumonia
(UIP) (B, ×12.5). A lung specimen stained with Elastica van Gieson
(EVG) demonstrates deposition of dense elastic fibers (elastosis) in a
subpleural fibrotic lung lesion (C, ×12.5). HRCT of the right lower
lobe shows pleural thickening and consolidation opacities along a
bronchovascular bundle with traction brochioloectasis (D). An
HE-stained lung section from the right lower lobe shows a UIP-like
lesion (E, ×12.5), and a EVG-stained specimen shows fewer elastic fibers
in the right lower lobe (F, ×12.5) than in the right upper lobe (C) in the
same patient. In this patient, the elastic fiber score in the lower lobe
was 20.3%, whilst that in the upper lobe was 32.4%.
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pneumonia to the acquisition of lung specimens was sig-
nificantly longer in patients with IPPFE than in those with
IPF. Although the prognosis of symptomatic patients with
IPUF is reportedly poor [11], the prognosis of asympto-
matic patients may be relatively better. Otherwise, symp-
toms may not readily appear in the earlier stage of IPPFE
because the FVC before the acquisition of lung specimens
was significantly lower in patients with IPPFE than in
those with IPF. HRCT and pathological examination re-
vealed more consolidation and more organizing pneu-
monia in patients with IPPFE than in those with IPF. A
diagnosis of IPPFE should be comprehensively worked out
using these findings.
Accumulation of dense EF in the subpleural paren-
chyma is a specific pathological feature of IPPFE [2]. A
recent imaging study found a significant increase in the
proportion of EF in the alveolar septum in a varietyof types of interstitial pneumonia, regardless of their histo-
logic appearance [12]. Basically, collagen fibers and EF ac-
cumulate simultaneously in the fibrotic lesions of
interstitial pneumonias in humans [12,13], and synthesis
and deposition of elastin have been noted in bleomycin-
induced interstitial pneumonia in animals [14]. Further-
more, we recently reported that the amount of EF was a
significant prognostic factor in patients with IPF [15]. In
the present study, more than twice the amount of EF was
found in the lungs of patients with IPPFE than in those
with IPF by measurement with a CCD camera and ana-
lytic software. To our knowledge, this is the first study to
quantitatively evaluate the amount of EF in patients with
IPPFE. Although the presence of EF is necessary to pro-
vide physiological elastic recoil of the lungs, abnormal de-
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Figure 5 Heterogeneous deposition of elastic fibers in the
lungs of patients with idiopathic pleuroparenchymal
fibroelastosis (IPPFE). Lung specimens were obtained from the
both upper lobe and lower lobes in five of the six patients with IPPFE.
Elastic fiber scores (EF scores) in each lobe are shown (A). EF scores in
lower lobes were significantly lower than those in the upper lobes in
patients with IPPFE (median, 24.2% [range 20.3-26.5%] vs. 32.4% [range
24.9-39.6%], p = 0.048). Values in the same patient are connected by
solid lines. The horizontal bar represents the median. Even in the lower
lobes, the EF scores in patients with IPPFE were still higher than those
in patients with IPF (C, p < 0.0001) as well as in the upper lobes
(B, p = 0.0007).
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of lungs and increase the work of breathing in the early in-
spiratory phase because of enhanced elastic recoil. There
is a possibility that this increase in respiratory workload
owing to an excess amount of EF may be related to the
lower body mass index and frequent pneumothoraces
seen in patients with IPPFE.
Although the prognosis of IPPFE is variable [2], some
studies have reported a poor prognosis in patients with
IPPFE/IPUF [6,11]. In the present study, three of the six
patients with IPPFE died of disease progression, and the
decrease in ΔFVC during the 12-month period after
biopsy was relatively substantial (-0.51 ± 0.35 L). Although
the survival of patients with IPPFE was not significantlydifferent from that of patients with IPF because of the
short observation period, it seems that the prognosis of
IPPFE is even poorer than that of IPF. A relationship
between the amount of EF and the prognosis was not
evident in this study. Therefore, parameters with which to
predict the prognosis in patients with IPPFE are necessary,
and larger studies are required to identify such parameters.
In the present study, significantly lower amounts of EF
were found in the lower lobes than in the upper lobes of
patients with IPPFE. Reddy et al. also presented a case
involving a patient with a lower amount of EF in the
lower lobe, which showed a typical UIP-pattern [6].
These findings suggest that typical dense elastosis may
be present only in the upper lobes in patients with
IPPFE, and biopsy specimens from the lower lobes may
contribute to misdiagnosis of IPF/UIP [7]. However, our
quantitative study revealed that the amount of EF in
patients with IPPFE was still higher, even in the lower
lobes, than in patients with IPF. These findings may lead
to an accurate histological diagnosis of IPPFE.
The pathophysiology and clinical cause of IPPFE remain
unclear. Some patients possess a familial history [2,6],
medical history of chemotherapy [2] or recurrent infection
[6], lung transplantation [17], or are positive for autoanti-
bodies [6]. Furthermore, overexpression of transforming
growth factor-α (TGF-α) may induce progressive intersti-
tial and pleural fibrosis with body weight loss [18,19], and
these changes are independent of TGF-β [19]. However,
the etiology of IPF is reportedly related to abnormal
wound healing in response to multiple microscopic sites
of ongoing alveolar epithelial injury [20] and is largely
dependent on TGF-β [21]. Therapeutic strategies should
differ between the two diseases because of their different
pathophysiologies. Therefore, an accurate diagnosis is
extremely important to establish novel treatments of each
disease in the near future.
Our study has a number of limitations. The number of
patients with biopsy-proven IPPFE was extremely small.
We hesitated to conduct surgical lung biopsy because
of the frequent occurrence of refractory pneumothorax
after biopsy [7]. Another limitation is that the study
period was relatively short. Finally, this study was con-
ducted retrospectively.
In this study, six patients with IPPFE included only one
female. The sex distribution in patients with IPPFE/IPUP
is very different between Japan and America/Europe.
Many Japanese case reports have described elderly male
patients with IPPFE/IPUF [22-24], whilst more patients
with IPPFE in America and Europe are younger female
[2,6,7]. This may be because of ethnic differences. Ad-
ditionally, all of these previous papers were case reports or
retrospective studies. Therefore, a large prospective and
longitudinal cohort study would be the ideal design by
which to clarify these issues.
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We found clinical, radiological, and pathological differ-
ences between IPPFE and IPF that will help clinicians to
properly diagnose IPPFE. Patients with IPPFE exhibited
a longer period from detection of interstitial pneumonia
to acquisition of lung specimens, a lower incidence of
fine crackles, more consolidation on HRCT, and more
organizing pneumonia on lung specimens than did pa-
tients with IPF. The FVC in patients with IPPFE before
biopsy was lower than that in patients with IPF, whilst
the decline in FVC after biopsy was comparable with
that in patients with IPF. In addition, more than twice
the amount of EF was found in the lungs of patients
with IPPFE than in the lungs of patients with IPF.
Although a lower amount of EF was found in the lower
lobes than in the upper lobes among patients with
IPPFE, the amount of EF was still higher than that in pa-
tients with IPF, even in the lower lobes.
It seems that refractory pneumothorax after surgical
lung biopsy of the upper lobes readily occurs in patients
with IPPFE [7]. Therefore, we believe that diagnosis of
IPPFE should be performed without surgical lung biopsy
in the future. The present clinical and radiological fin-
dings in addition to some surrogate biological marker
data may lead to an accurate diagnosis of IPPFE. Larger
studies will be necessary to clarify this.Additional file
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